Difference between revisions of "Cladribine (Leustatin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Acute myeloid leukemia]] | ||
| + | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
| + | *[[Hairy cell leukemia]] | ||
| + | *[[Mantle cell lymphoma]] | ||
| + | *[[Marginal zone lymphoma]] | ||
| + | *[[Mast cell diseases]] | ||
| + | *[[Waldenström macroglobulinemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 2/26/1993: Initial FDA approval | ||
==Also known as== | ==Also known as== | ||
| Line 30: | Line 42: | ||
[[Category:Mast cell diseases]] | [[Category:Mast cell diseases]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1993]] | ||
Revision as of 15:16, 7 November 2014
General information
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Hairy cell leukemia
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mast cell diseases
- Waldenström macroglobulinemia
Patient drug information
- Cladribine (Leustatin) patient drug information (Chemocare)[3]
- Cladribine (Leustatin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2/26/1993: Initial FDA approval
Also known as
2-chlorodeoxyadenosine, 2-CdA, Litak, Movectro
References
Categories:
- Drug index
- Antimetabolites
- Purine analogues
- Chemotherapy
- Irritant chemotherapy
- Nucleic acid analogs
- Acute myeloid leukemia medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Hairy cell leukemia medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mast cell diseases
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 1993